SER
****Sponsored by LFG Equities Corp
SER founders developed the first-generation of “PEGylated” drugs, which became the standard for delivery of protein drugs and has enabled 30 FDA approved products that have since generated over $140B in cumulative sales
Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 for theTreatment of Advanced Parkinson’s disease
Enrollment and dosing completed in Cohort 1 of Phase 1b registrational study of SER-252
Check Out the Investor Presentation Here
________________________________
Hello Everyone,
We are back with a new situation for you to research going into today's session. Digging into the numbers, this one stands out for a genuinely tight float — just around 11.15 million shares according to Yahoo. Combine that with only 25 million shares outstanding and 86% insider ownership, and you've got a share structure that's about as favorable as it gets. A setup like this means trading activity can get amplified fast once volume picks up. Add in a couple of notable analyst price targets plus a steady drumbeat of corporate updates signaling real developmental progress, and it's easy to see why this NYSE American-listed biotech is starting to catch traders' attention.
Pull up SER right away.
With a focus on next-generation molecules, their work spans diverse central nervous system disorders and beyond.
SER has ongoing collaborations with specialized partners that support the exploration of novel RNA-based medicines targeting vaccine immunology, cancer immunotherapy, and gene therapy.
This forward-thinking approach to drug discovery highlights a commitment to unlocking new possibilities in medicine, making the company well worth closer attention for those interested in emerging therapeutic frontiers.
This one has an interesting story behind it. The founders already did it once. This company was founded in 2007 and was largely funded by the founders and certain investors who followed the team to Serina after the successful exit (via acquisition by Nektar Therapeutics) of the founding team’s prior company, Shearwater Polymers.
At Shearwater, Serina co-founders Dr. Milton Harris and Dr. Michael Bentley developed the first-generation of “PEGylated” drugs. PEG (polyethylene glycol) technology became the standard for delivery of protein drugs and has enabled 30 FDA approved products that have since generated over $140B in cumulative sales. Serina was founded to engineer a next generation polymer therapeutic (our POZ PlatformTM) to address the limitations of PEG and other biocompatible polymer technologies -- enabling new treatment paradigms for patients suffering from some of the world’s most challenging diseases.
Serina Therapeutics' proprietary POZ platform is built on a synthetic, water-soluble, low-viscosity polymer known as poly (2-oxazoline).
During the synthesis process, a precise amount of drug is incorporated onto the polymer backbone using pendant alkyne groups and metal-catalyzed “click chemistry.”
This POZ technology enables enhanced control over drug loading and allows for more precise management of drug release rates.As a result, drugs with narrow therapeutic windows can be engineered to maintain more desirable and stable blood concentrations.
While optimized for small molecules, the platform is also applicable to proteins, aptamers, and other classes of molecules.
Serina Therapeutics is building a pipeline centered on next-generation compounds aimed at treating central nervous system disorders, while also extending its reach into broader therapeutic categories. Through partnerships with specialized research groups, the company is exploring RNA-based technologies with applications spanning vaccine science, oncology immunotherapy, and gene therapy.
The overarching objective is ambitious but clear: to push the boundaries of what modern drug design and delivery can achieve.
RECENT HIGHLIGHTS
- SER-252 Phase 1b Registrational Clinical Study: Following completion of sentinel dosing and the independent Safety Monitoring Committee’s recommendation to continue dosing, Serina completed enrollment and dosing of all eight patients in Cohort 1 in July 2026. The milestone was achieved ahead of the Company’s previously disclosed guidance of the end of the third quarter of 2026. The study protocol provides for a blinded review of Cohort 1 safety and tolerability observations by the independent Safety Monitoring Committee to inform the next dose-escalation decision. Top-line data from the single-ascending-dose arm remain targeted for the first half of 2027.
- Development Partnership with Gannet BioChem: In June 2026, Serina entered into a development partnership with Gannet BioChem to support process development, scale-up and manufacturing activities for SER-252. The collaboration expands the technical capabilities supporting the continued advancement of Serina’s lead clinical program and broader pipeline.
- Board Appointment: In July 2026, Serina appointed Farrell Simon, Pharm.D., to its Board of Directors and its Audit and Compensation Committees. Dr. Simon brings experience across commercial strategy, operations, business development and investor engagement, including his current role as Chief Commercial Officer of Trevi Therapeutics and prior senior leadership roles at Pfizer.
Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 for theTreatment of Advanced Parkinson’s disease
- Phase 1b clinical site start-up and regulatory activities in Australia underway tosupport the global registrational program
-HUNTSVILLE, AL, Jan 28, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” orthe "Company") (NYSE American: SER), a clinical-stage biotechnology company advancingdrug candidates enabled by its proprietary POZ PlatformTM drug optimization technology,today announced that the U.S. Food and Drug Administration (FDA) has cleared itsInvestigational New Drug (IND) application for SER-252, an investigational therapy for advanced Parkinson’s disease.The IND clearance allows Serina to proceed with regulatory and site-level activities to support initiation of a planned Phase 1b registrational clinical study evaluating SER-252 inpatients with advanced Parkinson’s disease.“FDA clearance of the IND is a major milestone for Serina and underscores the promise of the SER-252 program,” said Steve Ledger, Chief Executive Officer of Serina Therapeutics. “As we initiate our registrational study, we will begin generating meaningful clinical data for SER252 in patients with advanced Parkinson’s disease. With FDA alignment on a registrational development strategy under a 505(b)(2) NDA pathway, we believe SER-252 has a clear andefficient path forward toward addressing a significant unmet medical need.”As previously disclosed, Serina has engaged in multiple regulatory interactions with the FDAregarding the SER-252 program, including receipt of written FDA feedback supporting the proposed registrational clinical trial design under a 505(b)(2) NDA pathway.
Platform Science: A Polymer-Based Approach
At the center of Serina’s strategy is its proprietary poly(2-oxazoline) (POZ) polymer technology. This synthetic, water-soluble polymer allows drug molecules to be chemically linked along a controllable backbone using precision “click chemistry.” The result is tighter control over how much drug is attached and how quickly it is released once administered.
This level of control is especially relevant for therapies with narrow therapeutic windows, where maintaining stable blood concentrations can be critical to both efficacy and safety. While initially optimized for small molecules, the platform is adaptable to biologics, nucleic acids, and other advanced therapeutic classes.
Differentiation from PEG
POZ is positioned as a next-generation alternative to polyethylene glycol (PEG), a commonly used drug-delivery polymer. One of PEG’s known limitations is the potential for immune responses and antibody formation in some patients. POZ is engineered to reduce this immunogenicity risk while preserving favorable drug-delivery properties.
Why Sustained Delivery Matters in Neurology
Neurological treatments — including those for Parkinson’s disease — often require frequent dosing because drug levels rise and fall quickly in the bloodstream. These fluctuations can lead to variable symptom control, increased monitoring needs, and challenges with adherence and quality of life.
Serina’s platform is designed to address this by enabling longer-acting, subcutaneous formulations that release medication gradually, potentially smoothing out those peaks and troughs.
Pipeline Focus
Serina’s lead candidate, SER-252, targets advanced Parkinson’s disease. The therapy is intended to deliver sustained dopaminergic stimulation through extended drug release, with clinical trials anticipated to begin in 2025.
Beyond Parkinson’s, the company continues to evaluate additional CNS indications and maintains platform collaborations exploring RNA-based therapeutics for immunology and gene-related applications.
In sum, Serina Therapeutics represents an early-stage biotech story built around a differentiated drug-delivery platform, a neurology-focused pipeline, and multiple upcoming development milestones. The combination of scientific ambition, clinical progress, and market structure dynamics explains why the company has emerged as a name of interest among speculative biotech watchers.
POZ Delivers Key Advantages
POZ is engineered to address the limitations of PEG (polyethylene glycol) and other biocompatible polymers – such as immunogenicity, where unlike PEG, POZ does not elicit an immune response or stimulate development of antibodies to the polymer itself.
Enabling Continuous Drug Delivery
Many drugs, for example those used to treat neurological disorders like Parkinson’s, have narrow therapeutic ranges in which they can work safely and efficaciously.
They are often dosed more frequently – resulting in large and frequent fluctuations in drug exposure.
They have to be monitored and dose adjusted with greater frequency, and on an individual basis.
These fluctuations present clinical, compliance and quality of life challenges for many patients.
Administered Subcutaneously, POZ Provides Extended Delivery
Serina is in the process of developing proprietary drugs to treat neurological diseases. Their lead product candidate, SER-252 for advanced Parkinsons Disease, is anticipated to enter clinical trials in 2025. Their current discovery and development work includes a focus on unlocking the potential of cannabinoids and other molecules across a range of CNS indications and beyond. Their POZ platform partners are at the forefront in advancing novel RNA medicines in vaccine immunology, cancer immunoRX, and gene therapy.
Their proprietary POZ platform technology has been designed for programmable, targeted delivery of a broad range of small molecules. The technology has been clinically demonstrated to safely enable continuous drug delivery via a once weekly subcutaneous injection. The POZ platform is customizable, versatile and can be Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ PlatformTM provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs).
The technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Serina’s POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. The therapeutic agents in Serina’s product candidates are typically well-understood and marketed drugs that are effective but are limited by pharmacokinetic profiles that can include toxicity, side effects and short half-life. Serina believes that by using POZ technology, drugs with narrow therapeutic windows can be designed to maintain more desirable and stable levels in the blood.
Serina’s POZ platform delivery technology has potential for use across a broad range of payloads and indications. Serina intends to advance additional applications of the POZ platform via out-licensing, co-development, or other partnership arrangements, including the non-exclusive license agreement with Pfizer, Inc. to use Serina’s POZ polymer technology for use in lipid nanoparticle drug (LNP) delivery formulations.
About SER-252 (POZ-apomorphine)
SER 252 is an investigational apomorphine therapy developed with Serina’s POZ platform and designed to provide continuous dopaminergic stimulation (CDS). CDS has been shown to reduce the severity of levodopa-related motor complications (dyskinesia) in Parkinson’s disease. Preclinical studies support the potential of SER 252 to provide CDS without skin reactions. Serina plans to advance SER 252 to clinical testing in 2025.
Their proprietary POZ platform is based on a synthetic, water soluble, low viscosity polymer called poly (2-oxazoline). During the synthesis steps, a predictable amount of drug is incorporated on the backbone of the polymer using pendant alkyne groups and metal catalyzed “click chemistry”.
POZ technology provides greater control in drug loading, and the rate of release of attached drugs can often be more precisely controlled. Drugs with narrow therapeutic windows can be designed to maintain more desirable and stable levels in the blood. The technology is optimized for small molecules and can also be applied to proteins, aptamers and other classes of molecules.
Their largest shareholder, Juvenescence Ltd. recently secured $150 million in Series B financing led by M42, a global tech-enables health company headquartered in Abu Dhabi.
This significant investment and accompanying strategic alliance will accelerate Juvenescence’s mission to develop innovative therapies targeting age-related diseases and extending healthspan. As part of this partnership, Juvenescence and M42 will launch a drug development hub in Abu Dhabi, combining AI-enabled drug discovery with cutting-edge data and clinical infrastructure to speed the development of novel therapeutics.
Juvenescence has been a critical partner to Serina, providing strategic guidance and capital that has helped them advance their POZ Platform™ into the clinic.
NEWS
Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
Aug 13, 2026•
Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
Jul 24, 2026•
Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson’s Disease
Jul 23, 2026•
Serina Therapeutics Appoints Farrell Simon to its Board of Directors
Jul 22, 2026•
Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease
Jul 9, 2026•
Gannet BioChem and Serina Therapeutics Enter Development Partnership Supporting SER-252 Program
Jun 30, 2026•
Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
May 14, 2026•
Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit
Apr 7, 2026•
Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan
Apr 2, 2026•
Serina Therapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights
Mar 25, 2026
MANAGEMENT
Simba Gill, Ph.D.
Executive Chairman
Simba has a wealth of biotech and pharma experience in building companies and transformative platforms as well as developing products, having served in key executive roles at Maxygen, Systemix, Boehringer Mannheim and Celltech over his thirty-year career. He has served as a partner and advisor at Flagship Pioneering where he was the founding CEO of Evelo Biosciences and as a Venture Partner at TPG where he was Founder CEO of Moksh8 Pharmaceuticals. Simba is currently a board member at Foghorn Therapeutics (NASDAQ – FHTX) and Sensorium Therapeutics. He earned his MBA at INSEAD and received his Ph.D. from King’s College, London.
Steve Ledger
CEO and Director
Steve has served as CEO since March 2024 and CFO from March 2022 to March 2024. He has more than 35 years of experience as an investor, board member, advisor, and in operational roles with early-stage companies. He is a General Partner of Form & Fiction Ventures (FFV), a venture studio that launches and invests in startup and seed stage companies focused on socially responsible initiatives. He has served in investment management roles at Caldwell Sutter Capital, Tamalpais Partners, SF Sentry Securities, Kayne Anderson, and Fidelity Investments. Mr. Ledger received a B.A. in Economics from the University of Connecticut.
Randall
Randall Moreadith, M.D., Ph.D.
Chief Development Officer
Randall has served as Serina’s CDO since March 2024. He served as Serina’s President, CEO, and member of Serina’s board of directors from September 2010 to March 2024. Prior to Serina, Randall served in executive leadership roles including CDO at Nektar Therapeutics, CMO of Cardium Therapeutics, CMO at Renovis, and President / co-Founder of ThromboGenics (now Oxurion). Dr. Moreadith received his M.D. from Duke University and is trained clinically in Internal Medicine and Cardiovascular Diseases. Following his Fellowship in Cardiology at Duke University, he joined the laboratory of Professor Philip Leder where he was a Howard Hughes Medical Institute Fellow in Genetics at Harvard Medical School. Dr. Moreadith received his Ph.D. from Johns Hopkins University.
Greg Curhan
CFO
Greg joined Serina as CFO in August 2024. He has over 35 years of operational, financial, capital markets and strategic advisory experience in various sectors including Investment Banking and Medical Device/Life Sciences. Greg has been a Partner at FLG Partners since 2020. Also since 2020, Greg has served as the CFO for Curevo Vaccines, a private biotech company focused on infectious disease immunology. As CFO, Greg has managed Finance, Legal, HR, and Investor Relations functions for Public and Private companies. He has raised equity and debt capital for both private and public companies, completed numerous successful IPOs, and executed M&A transactions, both acquiring and divesting companies. He has also served in CEO, President and Board of Director capacities. Greg earned a BA degree in Economics from Dartmouth College.
Sincerely,
